日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial

认知障碍与绝经前和绝经后妇女的化学内分泌治疗与内分泌治疗:RxPONDER随机临床试验的二次分析

Kang, Irene M; Forschmiedt, Jamie K; Loch, Michelle M; Lew, Danika L; Barlow, William E; Gralow, Julie R; Meric-Bernstam, Funda; Albain, Kathy S; Hayes, Daniel F; Lin, Nancy U; Perez, Edith A; Goldstein, Lori J; Rastogi, Priya; Schott, Anne F; Baehner, Rick; Sharma, Priyanka; Tripathy, Debasish; Pusztai, Lajos; Hortobagyi, Gabriel N; Kalinsky, Kevin; Henry, N Lynn

303. PATIENT AND CLINICIAN ACCEPTANCE OF RECENT TECHNOLOGICAL ADVANCES IN THE THERAPEUTIC MONITORING OF LITHIUM

303. 患者和临床医生对锂治疗监测领域最新技术进步的接受度

Northrop, Anna; Christofferson, Anika; Umashankar, Saumya; Melisko, Michelle; Castillo, Paolo; Brown, Thelma; Heditsian, Diane; Brain, Susie; Simmons, Carol; Hieken, Tina; Ruddy, Kathryn J; Mainor, Candace; Afghahi, Anosheh; Tevis, Sarah; Blaes, Anne; Kang, Irene; Asare, Adam; Esserman, Laura; Hershman, Dawn L; Basu, Amrita; Dodd, S; Pedraza-Sanabria, S; Paredes Castro, A M; Williams, L J; Giraldo-Cadavid, L F; Bustos, R H

Clinical Actionability of Molecular Targets in Multi-Ethnic Breast Cancer Patients: A Retrospective Single-Institutional Study

分子靶点在多种族乳腺癌患者中的临床可操作性:一项回顾性单中心研究

Kang, Irene; Naghi, Leah; Yost, Susan E; Mortimer, Joanne

Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

帕博利珠单抗联合骨修饰剂治疗女性乳腺癌患者的疗效及免疫相关不良事件

LeVee, Alexis; Peluso, Esther; Lechner, Melissa G; Ruel, Nora; Mortimer, Joanne; Kang, Irene; Tsai, Karen

Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer

帕博利珠单抗标准间隔给药与延长间隔给药治疗乳腺癌患者的安全性和临床疗效比较

LeVee, Alexis; Kordic, Austin; Ruel, Nora; Mortimer, Joanne; Kang, Irene; McArthur, Heather; Lechner, Melissa G; Tsai, Karen

Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancer.

肿瘤相关 MerTK 促进促炎微环境,增强三阴性乳腺癌对免疫检查点抑制剂的反应

Crossman Bridget E, Harmon Regan L, Iida Mari, Adams Jillian M, Lin Candie Y, Glitchev Christine E, Juang Terry D, Kerr Sheena C, Alexandridis Roxana A, Hyun Meredith, Yang David T, Kang Irene, Salgia Ravi, Wheeler Deric L

Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy

靶向代谢脆弱性以对抗癌症治疗中的耐药性

Khan, Taranatee; Nagarajan, Manojavan; Kang, Irene; Wu, Chunjing; Wangpaichitr, Medhi

Integrated Proteogenomic Analysis Reveals Distinct Potentially Actionable Therapeutic Vulnerabilities in Triple-Negative Breast Cancer Subtypes

整合蛋白质基因组学分析揭示三阴性乳腺癌亚型中独特的、潜在可操作的治疗弱点

Kaur, Pushpinder; Ring, Alexander; Porras, Tania B; Zhou, Guang; Lu, Janice; Kang, Irene; Lang, Julie E

Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cells

靶向犬尿氨酸途径:癌症与免疫细胞代谢相互作用中的又一治疗契机

Kang, Irene; Theodoropoulos, George; Wangpaichitr, Medhi

Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer

对不同转移性免疫微环境中免疫标志物的评估表明,乳腺癌肝转移灶内的免疫抑制更为显著。

Hsu, Robert; Al-Zubeidy, Batul; Flores, Daniel; Nazarian, Ari; Baugh, Aaron; Gonzalez, Edgar; Castanon, Sofi; Xiu, Joanne; Kang, Irene; Spicer, Darcy; Lenz, Heinz Josef; Dara, Lily; Ademuyiwa, Foluso O; Korn, W Michael; Irshad, Sheeba; Chan, Isaac S; Roussos Torres, Evanthia T